GPT and metabolic dysfunction-associated steatotic liver disease: In fact, patients with LSM ≥8 kPa in our study were all included in the subgroup of “at-risk NAFLD” (i.e., patients with elevated ALT, diabetes, dyslipidemia or BMI ≥25 kg/m2), reinforcing the concept of targeted AdLF case-finding in patients with liver-risk factors, rather than non-targeted screening procedures in supposed at-risk populations such as CAD patients [36].